The stock of Ocular Therapeutix Inc (NASDAQ: OCUL) has increased by 9.87 when compared to last closing price of 7.65.Despite this, the company has seen a gain of 29.31% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-06 that Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Is It Worth Investing in Ocular Therapeutix Inc (NASDAQ: OCUL) Right Now?
Additionally, the 36-month beta value for OCUL is 1.46. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OCUL is 133.91M and currently, short sellers hold a 8.66% ratio of that float. The average trading volume of OCUL on March 11, 2025 was 1.03M shares.
OCUL’s Market Performance
OCUL stock saw an increase of 29.31% in the past week, with a monthly gain of 11.03% and a quarterly increase of -8.44%. The volatility ratio for the week is 8.95%, and the volatility levels for the last 30 days are 6.36% for Ocular Therapeutix Inc (OCUL). The simple moving average for the past 20 days is 17.13% for OCUL’s stock, with a 1.57% simple moving average for the past 200 days.
Analysts’ Opinion of OCUL
TD Cowen gave a rating of “Buy” to OCUL, setting the target price at $11 in the report published on June 20th of the previous year.
OCUL Trading at 8.50% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.62% of loss for the given period.
Volatility was left at 6.36%, however, over the last 30 days, the volatility rate increased by 8.95%, as shares surge +12.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, OCUL rose by +28.15%, which changed the moving average for the period of 200-days by +36.56% in comparison to the 20-day moving average, which settled at $7.17. In addition, Ocular Therapeutix Inc saw -1.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from Dugel Pravin, who sale 21,475 shares at the price of $6.87 back on Feb 24 ’25. After this action, Dugel Pravin now owns 3,520,318 shares of Ocular Therapeutix Inc, valued at $147,533 using the latest closing price.
Heier Jeffrey S., the Chief Scientific Officer of Ocular Therapeutix Inc, sale 3,061 shares at $6.87 during a trade that took place back on Feb 24 ’25, which means that Heier Jeffrey S. is holding 265,998 shares at $21,029 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -2.7 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -3.04. The total capital return value is set at -0.41. Equity return is now at value -95.21, with -54.51 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -1.78. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -12.65.
Currently, EBITDA for the company is -176.14 million with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 15.61. The receivables turnover for the company is 1.97for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.66.
Conclusion
In conclusion, Ocular Therapeutix Inc (OCUL) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
